Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

← catalyst calendar

NCT04452591 · readout in 1,397 d

Sponsored by CG Oncology, Inc. (industry) · CGON — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

190estimated

Sites

Countries

Australia, Canada, Japan +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-10-27

actual

When the study began enrolling

Primary completion

2030-06-16

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-12-24

estimated

The whole study's end, after follow-up

First posted

2020-06-30

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non Muscle Invasive Bladder Cancer
High-grade Ta/ T1 Papillary Disease Bladder Cancer

Interventions

Biological: Cretostimogene Grenadenorepvec
Other: n-dodecyl-B-D-maltoside — also filed as DDM

Primary outcomes

what the primary-completion date above is the date OF

Cohort C:

measured 36 months

Cohort P:

measured 36 months

Publications

PMID 42508433 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CGON's whole pipeline · Catalyst calendar · Every registered study · What changed